Krista Tantakoun
Associate Manager, Value & Evidence
专长:
As an Associate Manager on the Value & Evidence team at EVERSANA™, Krista contributes to evidence synthesis projects that support global HEOR initiatives.
Since joining the team in 2020, Krista has been involved in activities that address pharmaceutical and/or medical device-related research such as systematic and targeted literature reviews, feasibility assessments, indirect treatment comparisons, and real-world data analysis. She has experience developing high-quality deliverables including technical reports, manuscripts, and conference presentations. Her work has focused on several therapeutic areas in oncology (breast cancer, multiple myeloma, renal cell carcinoma, prostate cancer) and rare diseases.
Krista holds a MSc degree in International Health Technology Assessment and Reimbursement from the University of Sheffield. In addition, she holds a Graduate Diploma in Clinical Epidemiology from McMaster University and a BSc degree in Nutritional & Nutraceutical Sciences from the University of Guelph.
Articles by Krista Tantakoun
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan drug submissions incorporating ITCs to support regulatory decisions and health technology assessment (HTA) recommendations. The Value & Evidence team […]
A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices
Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national […]